2 results
Approved WMOCompleted
To characterize safety, tolerability, pharmacodynamic effects, and pharmacokinetics of the oral sGC stimulator BAY 1021189 in addition to standard therapy for heart failure with reduced EF (HFrEF) over 12 weeks in patients with worsening chronic…
Approved WMOCompleted
Primary objective:To assess the effects of firibastat (QGC001) administered at 1000 mg orally (po) once daily (QD) on blood pressure (BP) over 12 weeksSecondary objectives:• To assess the safety of firibastat (QGC001) administered at 1000 mg po QD…